Kessler Paul D. 4
4 · NABI BIOPHARMACEUTICALS · Filed Apr 9, 2012
Insider Transaction Report
Form 4
Kessler Paul D.
SVP Clinical, Med. & Reg.; CMO
Transactions
- Sale
Common Stock
2012-04-05$1.90/sh−5,167$9,817→ 105,128 total
Footnotes (1)
- [F1]This disposition was effected pursuant to a 10b-5 trading plan and was made to fund the Reporting Person's tax obligation arising from the vesting of restricted stock.